Pharmacogenetic Features of Therapy of Patients With Atherosclerosis

Хохлов, А. Л.; Iavorskiĭ, A N; Поздняков, Н. О.; Рыбачкова, Ю В; Емельянов, Е. С.; Хохлов, А. А.; Мирошников, А. Е.; Поздняков, С. О.

doi:10.20514/2226-6704-2018-8-1-45-52

Cited by 4 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Полученные результаты вносят в инструкцию по применению лекарственных средств [25]. Для того, чтобы спрогнозировать как организм больного среагирует на лечение, необходимо сосредоточиться на вариантах генного кодирования (ферментах, переносчиках, клетках-мишенях) и провести анализ гаплотипов человеческого лейкоцитарного антигена [26]. С 2015 г. к ста семидесяти четырем лекарственным препаратам была приложена фармакогеномная метка, показывающая насколько информативно будет проведение генотипирования пациента в отношении данного препарата.…”

Section: резюмеunclassified

Omics technologies in the diagnosis of oncological diseases

Loginova,

Kirch,

Lyalyukova

et al. 2023

jour

View full text Add to dashboard Cite

High mortality and disability from cancer remains one of the important and unresolved issues of modern medicine. Experts of WHO consider, that cancer is the second leading cause of death worldwide. Approximately 9 million people die of cancer each year, and more than 14 million are diagnosed with cancer. At the same time, according to Russian epidemiology, there is a trend to increase of cases of cancer, including people of young working age, and there is no reliable, verified information about the causes and mechanisms of development of tumor cells. The patient may begin to complain too late, so it is not always possible to suspect this and prevent the diseases. Many research centers and clinics are concerned about this problem and are deeply involved in solving it. To date, a promising direction in the diagnosis of oncological diseases are omics technologies, which are being studied, tested and gradually introduced into modern medicine. According to scientists, the future of healthcare lies with omics technologies, since they allow studying the whole patient’s genotype, which will allow to suggest a person’s predisposition to a particular disease very early, develop methods of correction and prevention, and select the most effective methods of treatment. The purpose of this review is to systematize domestic and foreign data on the current results of the use of omics technologies in the early diagnosis of oncological diseases.

show abstract

Section: резюмеunclassified

Omics technologies in the diagnosis of oncological diseases

Loginova,

Kirch,

Lyalyukova

et al. 2023

jour

View full text Add to dashboard Cite

show abstract

Genetic and nongenetic factors in assessing the prognosis of patients after myocardial infarction with high medical adherence

Переверзева

Якушин

Галус

et al. 2021

Cardiovasc Ther Prev

View full text Add to dashboard Cite

Aim. During one-year follow-up, to assess the effect of genetic and nongenetic factors on the risk of poor outcomes in patients after myocardial infarction (MI) with high medical adherence.Material and methods. The study included 250 patients admitted to the hospital due to MI in the period from September 1, 2018 to May 1, 2019 and with a potentially high medical adherence. Twelve months after MI, patients were assessed for adherence to therapy and the effect of genetic and nongenetic factors on the patient prognosis.Results. Within 12 months after MI, 70 (28,0%) patients had a composite endpoint: all-cause death, MI, cerebral stroke, and nonelective coronary revascularization. There were following factors increasing the risk of composite endpoint: non-Q-wave MI (relative risk (RR), 2,63; 95% confidence interval (CI): 1,63-4,25 (p=0,001); left ventricular ejection fraction ≤35% — RR, 2,03; 95% CI: 1,17-3,50 (p<0,0001); CYP2C19 GA/AA genotype (RR, 1,58; 95% CI: 1,06-2,37 (p<0,00001)).Conclusion. The study results allow identifying patients with a high risk of poor outcome: patients with non-Q-wave MI, left ventricular ejection fraction ≤35%, and CYP2C19 GA/AA genotype.

show abstract

Associations of Gene Polymorphisms and Prognosis in Highly Adherent to Treatment Patients After Myocardial Infarction

Переверзева

Якушин

Nikiforov

et al. 2021

Arhivʺ vnutrennej mediciny

View full text Add to dashboard Cite

Aim. To evaluate the influence of genetic factors on the risk of developing a combined endpoint, during a one-year supervision of patients, who had myocardial infarction and highly adherent to drug therapy.Material and methods. The research included 250 patients with high adherence to treatment with myocardial infarction, using the method of polymerase chain reaction we determined the polymorphisms Thr174Met and Met235Thr in the AGT gene, Arg389Gly and Ser49Gly in the ADRB1 gene, Ser447Ter in the LPL gene and Leu28Pro in the APOE gene, Trp212Ter and G681A in the CYP2C19 gene, and then we evaluated their influence on the prognosis.Results. A significant influence on the risk of developing combined endpoint was noticed for the polymorphism of CYP2C19 (G681A) gene. For the GA genotype of the CYP2C19 gene (G6881A), the OR of developing an unsuccessful outcome was 1.97 (95 % CI 1.05 — 3.69) (P = 0.03). For сarrier-state of A allele the OR was 1.46 (95 % CI 1.06 — 3.64) (P = 0.03). Conclusion. The results received indicate the need for individual approach for the choice of drugs from the group of inhibitors P2Y12-receptors for dual antiplatelet therapy, and if clopidogrel is chosen it is necessary to resolve the issue of pharmacogenetic testing for CYP2C19.

show abstract

Pharmacogenetic Features of Therapy of Patients With Atherosclerosis

Cited by 4 publications

References 4 publications

Omics technologies in the diagnosis of oncological diseases

Omics technologies in the diagnosis of oncological diseases

Genetic and nongenetic factors in assessing the prognosis of patients after myocardial infarction with high medical adherence

Associations of Gene Polymorphisms and Prognosis in Highly Adherent to Treatment Patients After Myocardial Infarction

Contact Info

Product

Resources

About